Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Oscotec Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03564288
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Clinical Investigations Support Office (CISO), 1441 Eastlake Ave., Rm. 7327, Los Angeles, California, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 10
- Registration Number
- NCT03552029
- Locations
- 🇺🇸
Ronald Reagan Medical Center, UCLA, Los Angeles, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸University of Kansas Cancer Center, Fairway, Kansas, United States
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Acute Myeloid Leukemia (AML)Marginal Zone Lymphoma (MZL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Small Lymphocytic Lymphoma (SLL)
- Interventions
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT03547115
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 64
- Registration Number
- NCT03541369
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Northwestern University, Evanston, Illinois, United States
🇺🇸Johns Hopkins, Baltimore, Maryland, United States
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2018-04-30
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 511
- Registration Number
- NCT03512197
- Locations
- 🇺🇸
University of Chicago Medical Center ., Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Oregon Health and Science Univ, Portland, Oregon, United States
CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia(AML)
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT03473457
- Locations
- 🇨🇳
Southern Medical University Zhujiang Hospital, Guangdong, Guangdong, China
A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT03441555
- Locations
- 🇺🇸
USC Norris Cancer Center /ID# 170844, Los Angeles, California, United States
🇺🇸UC Irvine /ID# 201093, Orange, California, United States
🇺🇸University of California, Davis Comprehensive Cancer Center /ID# 170799, Sacramento, California, United States
Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2022-10-26
- Target Recruit Count
- 21
- Registration Number
- NCT03410407
- Locations
- 🇮🇹
Aon Ss. Antonio E Biagio E C. Arrigo - Alessandria - Soc Ematologia, Alessandria, Italy
🇮🇹Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica, Ancona, Italy
🇮🇹Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto, Bari, Italy
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
- Conditions
- Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT03409081
- Locations
- 🇦🇺
Site AU61001, Canberra, Australia
🇮🇹Site IT39001, Milan, Italy
🇮🇹Site IT39003, Milan, Italy
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2018-01-03
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Moleculin Biotech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03388749
- Locations
- 🇵🇱
Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznań, Poland
🇵🇱Samodzielny Publiczny Szpital Kliniczny nr 1 im. Prof. Tadeusza Sokołowskiego w Szczecinie, Klinika Hematologii z Oddziałem Transplantacji Szpiku, Szczecin, Poland
🇵🇱Instytut Hematologii i Transfuzjologii, Klinika Hematologii, Warszawa, Poland